TY - JOUR T1 - Long-term response of upper airway stimulation in obstructive sleep apnea JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - 4313 AU - Wilfried De Backer AU - Johan Verbraecken AU - Lennart Knaack AU - Arie Oliven AU - Winfried Hohenhorst AU - Olivier Vanderveken AU - Paul Van de Heyning Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/4313.abstract N2 - Background: Previous studies identified patient selection criteria for therapy success in Upper Airway Stimulation (Inspire Medical Systems, USA) for treatment of moderate-to-severe OSA in patients intolerant to continuous positive airway pressure. The current study reported therapy response at 12-months post-implant in subjects who met selection criteria.Methods: Among 34 implanted subjects, 18 met criteria for responder and 16 did not. AHI (Level 1 monitoring) were measured at 12 months. All patients were monitored for device-related adverse events and patients met selection criteria were examined for therapy response during over-night PSG.Results: There were no device malfunctions or un-anticipated device-related adverse events from 6-12 months. Among patients who met selection criteria and for which data are available, the AHI reduction was maintained at 12-month. Improvement for ESS and FOSQ were also observed in these subjects from baseline to 6-month, 10.7 ± 5.4 to 7.5 ± 4.1 (p=0.03), and 88.8 ± 22.1 to 104.6 ± 13.7 (p=0.01) for ESS and FOSQ, respectively. AHI remained unchanged at 12-month for patients that did not meet selection criteria.View this table:Conclusion: The current study has demonstrated that Upper Airway Stimulation to treat OSA has a sustained therapy efficacy at 12-month post-implant in a selected group of moderate-to-severe OSA subjects. ER -